Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Active as of 2024-12-19

Generated Narrative: Citation 179629

version: 11; Last updated: 2024-11-22 19:27:51+0000

Profile: JournalArticleCitation

url: Citation 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179629, https://pubmed.ncbi.nlm.nih.gov/23604530, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.2

version: 2.0.0-ballot

title: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*Citation Classification Type fevir-platform-use: FEvIR Platform UseMedline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2013-08-01

lastReviewDate: 2021-11-22

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2013-02-14

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2013-04-08

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2013-04-23 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2013-04-23 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2013-08-02 06:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/23604530, https://doi.org/10.1007/s00280-013-2163-4

Titles

-TypeLanguageText
*Primary titleEnglish

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Abstracts

-Text
*

PURPOSE: Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation. METHODS: Enrolled patients received ADT in the form of leuprolide every 12 weeks for 24 months with bicalutamide initiating after the completion of chemotherapy. Chemotherapy consisted of ketoconazole and doxorubicin for weeks 1, 3, and 5 and estramustine and docetaxel and for weeks 2, 4 and 6. During weeks 7 and 8, no treatment was received. RESULTS: Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %). CONCLUSIONS: The treatment demonstrated clinical benefit in all patient subsets with minimal reversible treatment-related adverse events. Subgroup analysis suggests that having prior local therapy resulted in greater PFS and OS.

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1432-0843, ISOAbbreviation/Cancer Chemother Pharmacol, ISSN Linking/0344-5704, Medline Title Abbreviation/Cancer Chemother Pharmacol, NLM Unique ID/7806519

title: Cancer chemotherapy and pharmacology

publisherLocation: Germany

citedMedium: Internet

volume: 71

issue: 6

articleDate: 2013-06

publicationDateText: 2013-Jun

language: English

pageString: 1629-34

publicationForm

citedMedium: Internet without issue

articleDate: 2013-04-21

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/23604530/

webLocation

classifier: DOI Based

url: https://doi.org/10.1007/s00280-013-2163-4

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Chemical

classifier: Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Nitriles, Tosyl Compounds, bicalutamide, KLK3 protein, human, Kallikreins, Prostate-Specific Antigen, Leuprolide

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Clinical Trial, Phase II, Journal Article

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Amato R

forenameInitials: R

affiliation: Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston (Medical School)/Memorial Hermann Cancer Center, 6410 Fannin St., Suite 830, Houston, TX 77030, USA. robert.amato@uth.tmc.edu

entry

contributor: Stepankiw M

forenameInitials: M

entry

contributor: Gonzales P

forenameInitials: P


Generated Narrative: Practitioner #contributor0

name: Robert Amato


Generated Narrative: Practitioner #contributor1

name: Mika Stepankiw


Generated Narrative: Practitioner #contributor2

name: Patricia Gonzales


Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

content

type: components (if present) include qualifier codings

classifier: Adenocarcinoma

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-TypeClassifier
*is Major topicYes

component

type: qualifier

classifier: metabolism

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: pathology

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Aged, 80 and over

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Anilides

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Antineoplastic Agents, Hormonal

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Antineoplastic Combined Chemotherapy Protocols

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Disease-Free Survival

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Kallikreins

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: blood

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Leuprolide

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Neoplasm Grading

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Nitriles

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Prostate-Specific Antigen

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: blood

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Prostatectomy

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-TypeClassifier
*is Major topicYes

component

type: qualifier

classifier: metabolism

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: pathology

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Radiotherapy

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Tosyl Compounds

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Treatment Failure

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic